Small CDMO

Cohance Lifesciences Ltd.

COHANCE

Market Cap
₹17,198 Cr.
P/E
95.96

Cohance Lifesciences Ltd.

  • Cohance Lifesciences
  • Jubilant Pharmova
  • Syngene Internatl.
  • TJI Pharma - API & CRAMS

FAQs on Cohance Lifesciences Ltd. Shareprice

Cohance Lifesciences has given lower returns compared to its competitors.
Cohance Lifesciences has grown at ~-2.0% over the last 3yrs while peers have grown at a median rate of 15.0%

Cohance Lifesciences is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Cohance Lifesciences is 95.95, while 3 year average PE is 65.4.
Also latest EV/EBITDA of Cohance Lifesciences is 40.53 while 3yr average is 46.09.

View FAQ's On Business

Growth Table

  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Balance Sheet

  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Cash Flow

  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Quarterly Results

  • Cohance Lifesciences Ltd.
  • Jubilant Pharmova
  • Syngene Internatl.

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Cohance Lifesciences Ltd. Financials

Balance sheet of Cohance Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Cohance Lifesciences is increasing.
Latest net debt of Cohance Lifesciences is ₹110 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹99.17 Crs.

No, profit is decreasing.
The profit of Cohance Lifesciences is ₹150 Crs for TTM, ₹268 Crs for Mar 2025 and ₹300 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Cohance Lifesciences latest dividend payout ratio is 37.14% and 3yr average dividend payout ratio is 37.14%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech